KR20100075493A - 퇴행성 질환의 치료를 위한 신경내분비 인자 - Google Patents

퇴행성 질환의 치료를 위한 신경내분비 인자 Download PDF

Info

Publication number
KR20100075493A
KR20100075493A KR1020107007806A KR20107007806A KR20100075493A KR 20100075493 A KR20100075493 A KR 20100075493A KR 1020107007806 A KR1020107007806 A KR 1020107007806A KR 20107007806 A KR20107007806 A KR 20107007806A KR 20100075493 A KR20100075493 A KR 20100075493A
Authority
KR
South Korea
Prior art keywords
leu
ser
asn
arg
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107007806A
Other languages
English (en)
Korean (ko)
Inventor
아냐 보써호프
토마스 슈베르트
엘리자베스 후스테르트
Original Assignee
에스씨아이엘 테크놀로지 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by 에스씨아이엘 테크놀로지 게엠베하 filed Critical 에스씨아이엘 테크놀로지 게엠베하
Publication of KR20100075493A publication Critical patent/KR20100075493A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020107007806A 2007-09-14 2008-09-12 퇴행성 질환의 치료를 위한 신경내분비 인자 Withdrawn KR20100075493A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07018131.8 2007-09-14
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP08006810 2008-04-03
EP08006810.9 2008-04-03

Publications (1)

Publication Number Publication Date
KR20100075493A true KR20100075493A (ko) 2010-07-02

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107007806A Withdrawn KR20100075493A (ko) 2007-09-14 2008-09-12 퇴행성 질환의 치료를 위한 신경내분비 인자

Country Status (13)

Country Link
US (1) US20110002972A1 (https=)
EP (1) EP2212344B1 (https=)
JP (1) JP2010539123A (https=)
KR (1) KR20100075493A (https=)
CN (1) CN101821283A (https=)
AU (1) AU2008297889A1 (https=)
BR (1) BRPI0816784A8 (https=)
CA (1) CA2699411A1 (https=)
MX (1) MX2010002716A (https=)
NZ (1) NZ583851A (https=)
RU (1) RU2496790C2 (https=)
WO (1) WO2009033715A2 (https=)
ZA (1) ZA201001644B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
JP2014507395A (ja) * 2010-12-23 2014-03-27 サノフイ 肝癌の治療における使用のためのRobo1−Fc融合タンパク質
CA2839341C (en) * 2011-07-04 2020-12-15 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
US9802994B2 (en) * 2012-06-15 2017-10-31 The Asan Foundation Composition for preventing or treating fracture or osteoporosis using slit-robo system
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
JPWO2015072527A1 (ja) * 2013-11-13 2017-03-16 国立大学法人大阪大学 ネトリン1含有破骨細胞形成抑制剤
HUE068789T2 (hu) 2014-03-14 2025-01-28 Univ New York State Res Found A csontnövekedés és a csontlebontás neurogén szabályozása
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
WO2019161136A1 (en) * 2018-02-14 2019-08-22 Cornell University Slit and bone growth modulation
EP3932430A4 (en) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. ALBUMIN-RELATED COMPOSITION COMPRISING LRRD2 OF THE SLIT3 PROTEIN FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
AU2020346062A1 (en) * 2019-09-13 2022-03-24 Rutgers, The State University Of New Jersey AAV-compatible laminin-linker polymerization proteins
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
JP7851625B2 (ja) * 2021-07-26 2026-04-27 ピューロテックバイオ株式会社 宿主因子lipgをターゲットとした抗b型肝炎ウイルス剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1203999A (en) * 1997-10-31 1999-05-24 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US20030096955A1 (en) * 1998-09-01 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2365214A1 (en) * 1999-03-17 2000-09-21 Washington University Vertebrate protein slit, dna sequence encoding it and uses thereof
WO2002006315A2 (en) * 2000-07-18 2002-01-24 Compugen Ltd. Novel nucleic acid and amino acid sequences
JP2004527210A (ja) * 2000-08-02 2004-09-09 ザ ジョンズ ホプキンス ユニバーシティー 内皮細胞発現パターンの評価法
AU2001286446A1 (en) * 2000-08-10 2002-02-18 Pharmacia Corporation A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
US20040265808A1 (en) * 2001-04-05 2004-12-30 Teresa Garcia Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
BRPI0720038A2 (pt) * 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor

Also Published As

Publication number Publication date
CA2699411A1 (en) 2009-03-19
US20110002972A1 (en) 2011-01-06
RU2496790C2 (ru) 2013-10-27
MX2010002716A (es) 2010-07-05
EP2212344B1 (en) 2014-03-26
EP2212344A2 (en) 2010-08-04
JP2010539123A (ja) 2010-12-16
RU2010114713A (ru) 2011-10-20
BRPI0816784A8 (pt) 2016-01-19
WO2009033715A3 (en) 2010-03-18
ZA201001644B (en) 2011-03-30
BRPI0816784A2 (pt) 2015-03-24
AU2008297889A1 (en) 2009-03-19
NZ583851A (en) 2012-06-29
CN101821283A (zh) 2010-09-01
WO2009033715A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
EP2212344B1 (en) Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP2083846B1 (en) N-terminal fgf variants having increased receptor selectivity and uses thereof
AU2016203028A1 (en) Peptides and compositions for treatment of joint damage
US20020147329A1 (en) Method of modulating tissue growth using Frzb protein
Madry et al. Clinical potential and challenges of using genetically modified cells for articular cartilage repair
EP3250223A1 (en) Methods for the regeneration of articular cartilage in vivo
JP5856117B2 (ja) 細胞シグナル伝達タンパク質nell1を用いた、創傷治癒及び筋再生の促進方法
US20250345393A1 (en) Isoform nell-1 peptide
AU743744B2 (en) Novel morphogen-responsive signal transducer and methods of use thereof
KR100702725B1 (ko) Tgf-베타를 사용하는 유전자 요법
EP2036921A1 (en) Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
US20130288972A1 (en) Compositions and Methods For The Treatment of Orthopedic Disease or Injury
Aihaiti et al. The role of thrombospondins in osteoarthritis: from molecular mechanisms to therapeutic potential
US20030009023A1 (en) Isolation and method of using tissue growth-inducing Frzb protein
WO2019246013A1 (en) Peptides to enhance bone growth, repair and cell function
EP1192181B1 (en) Modulation of angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor for the treatment of tumor
EP1142579A2 (en) Bone resorption inhibitors
JP2003052387A (ja) 線維芽細胞増殖因子13

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100409

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20120309

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid